Evidence map›Paper›PMID 37822362›Full record

ArticleClinical medicine insights. Endocrinology and diabetes2023

CHILDSTAR: CHIldren Living With Diabetes See and Thrive with AI Review.

Katie Curran, Noelle Whitestone, Bedowra Zabeen, Munir Ahmed, Lutful Husain, Mohammed Alauddin, Mohammad Awlad Hossain, Jennifer L Patnaik, Gabriella Lanoutee, David Hunter Cherwek and 3 more

Open access · goldAbstract read
In one paragraph

Article in Clinical medicine insights. Endocrinology and diabetes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 4 countries.

Katie CurranCentre for Public Health, Queens University Belfast, Belfast, UK.ORCID https://orcid.org/0000-0002-7071-109X
Noelle WhitestoneOrbis International, New York, NY, USA.
Bedowra ZabeenDepartment of Paediatrics, Life for a Child & Changing Diabetes in Children Programme, Bangladesh Institute of Research & Rehabilitation in Diabetes, Endocrine & Metabolic Disorders (BIRDEM), Diabetic Association of Bangladesh, Dhaka, Bangladesh.
Munir AhmedOrbis Bangladesh, Dhaka, Bangladesh.
Lutful HusainOrbis Bangladesh, Dhaka, Bangladesh.
Mohammed AlauddinOrbis Bangladesh, Dhaka, Bangladesh.
Mohammad Awlad HossainOrbis International, New York, NY, USA.
Jennifer L PatnaikOrbis International, New York, NY, USA.
Gabriella LanouteeOrbis International, New York, NY, USA.
David Hunter CherwekOrbis International, New York, NY, USA.
Nathan CongdonCentre for Public Health, Queens University Belfast, Belfast, UK.
Tunde PetoCentre for Public Health, Queens University Belfast, Belfast, UK.
Nicolas JaccardOrbis International, New York, NY, USA.
Queen's University Belfast · GBBangladesh Institute of Research and Rehabilitation for Diabetes Endocrine and Metabolic Disorders · BDUniversity of Colorado Denver · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Artificial intelligence (AI) appears capable of detecting diabetic retinopathy (DR) with a high degree of accuracy in adults; however, there are few studies in children and young adults. Methods: Children and young adults (3-26 years) with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) were screened at the Dhaka BIRDEM-2 hospital, Bangladesh. All gradable fundus images were uploaded to Cybersight AI for interpretation. Two main outcomes were considered at a patient level: 1) Any DR, defined as mild non-proliferative diabetic retinopathy (NPDR or more severe; and 2) Referable DR, defined as moderate NPDR or more severe. Diagnostic test performance comparing Orbis International's Cybersight AI with the reference standard, a fully qualified optometrist certified in DR grading, was assessed using the Matthews correlation coefficient (MCC), area under the receiver operating characteristic curve (AUC-ROC), area under the precision-recall curve (AUC-PR), sensitivity, specificity, positive and negative predictive values. Results: Among 1274 participants (53.1% female, mean age 16.7 years), 19.4% (n = 247) had any DR according to AI. For referable DR, 2.35% (n = 30) were detected by AI. The sensitivity and specificity of AI for any DR were 75.5% (CI 69.7-81.3%) and 91.8% (CI 90.2-93.5%) respectively, and for referable DR, these values were 84.2% (CI 67.8-100%) and 98.9% (CI 98.3%-99.5%). The MCC, AUC-ROC and the AUC-PR for referable DR were 63.4, 91.2 and 76.2% respectively. AI was most successful in accurately classifying younger children with shorter duration of diabetes. Conclusions: Cybersight AI accurately detected any DR and referable DR among children and young adults, despite its algorithms having been trained on adults. The observed high specificity is particularly important to avoid over-referral in low-resource settings. AI may be an effective tool to reduce demands on scarce physician resources for the care of children with diabetes in low-resource settings.

Indexed as

Artificial intelligencechildrendiabetesdiabetic retinopathy screeningyoung adults

Identifiers

PMID37822362
PMCPMC10563496
OpenAlexW4387464357

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.